Stockscreener 앱 받기
19.27
0.77%
-0.15
전일 마감가:
$19.42
열려 있는:
$19.51
하루 거래량:
4.44M
Relative Volume:
1.52
시가총액:
$2.75B
수익:
-
순이익/손실:
$-412.89M
주가수익비율:
-4.9922
EPS:
-3.86
순현금흐름:
$-361.93M
1주 성능:
-4.98%
1개월 성능:
+3.55%
6개월 성능:
+33.26%
1년 성능:
-24.76%
1일 변동 폭
$19.20
$19.96
1주일 범위
$18.21
$23.96
52주 변동 폭
$6.36
$26.69
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.27 | 2.77B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-25 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Frazier Life Sciences Management L.P. Has $14.34 Million Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
TFG Asset Management GP Ltd Acquires New Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
Braidwell LP Has $31.16 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
WilmerHale Advises Dyne Therapeutics on its $402.5 Million Public Offering of Common Stock - WilmerHale
Why Dyne Therapeutics stock was a big winner on Wednesday - MSN
Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN) - theglobeandmail.com
HighVista Strategies LLC Sells 52,096 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Stifel Maintains Dyne Therapeutics (DYN) Buy Recommendation - Nasdaq
Dyne Therapeutics raises $402.5 million in upsized public offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics raises $402.5 million in upsized public offering - Investing.com
Dyne Therapeutics prices $350 stock offering - MSN
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $39.00 at Stifel Nicolaus - MarketBeat
Dyne, citing positive trial data, to ask FDA to approve DMD therapy - Muscular Dystrophy News
Stifel Raises Price Target for Dyne Therapeutics (DYN) to $39.00 - GuruFocus
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial - Insider Monkey
Dyne Therapeutics (DYN) Upgraded by Oppenheimer, Potential 50% U - GuruFocus
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday - Finviz
Oppenheimer Upgrades Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics Announces Upsized Public Offering - TipRanks
Dyne Therapeutics (DYN) Upgraded by Oppenheimer, Potential 50% Upside - GuruFocus
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
11 High Short Interest Stocks to Buy Right Now - Insider Monkey
Dyne Therapeutics (NASDAQ:DYN) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Dyne Therapeutics: Why The $350M Public Offering Was Critical (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics Surges Amid Positive Trial Results and Financial Adjustments - timothysykes.com
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
Oppenheimer Upgrades Dyne Therapeutics to Outperform From Perform, Adjusts PT to $40 From $11 - marketscreener.com
Dyne Therapeutics (DYN) Sees Upgrade and Potential Stock Upside - GuruFocus
HC Wainwright Has Positive Outlook for DYN FY2027 Earnings - MarketBeat
Dyne Therapeutics Prices $350 Million Public Offering - marketscreener.com
Dyne Therapeutics Prices Upsized Public Offering Of 18.98 Mln Shares - Nasdaq
Dyne Therapeutics prices upsized public offering at $18.44 per share - Investing.com
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - The Manila Times
Dyne Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Amounting to $350 Million - Quiver Quantitative
Dyne Therapeutics says co prices public offering at $18.44 per share - marketscreener.com
Dyne Therapeutics Says Co Prices Public Offering At $18.44 Per Share - TradingView — Track All Markets
Why Dyne Therapeutics Stock Tanked on Tuesday - The Globe and Mail
Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears - Markets Financial Content
Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More - The Motley Fool
Dyne Therapeutics stock tumbles on $300 million share offering By Investing.com - Investing.com Canada
Dyne Therapeutics stock tumbles on $300 million share offering - Investing.com
Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate - Finviz
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets - AOL.com
Dyne to seek accelerated approval of DMD drug on Phase I/II data - Yahoo Finance
Dyne Therapeutics (NASDAQ:DYN) Shares Gap DownHere's What Happened - MarketBeat
Dyne Therapeutics (DYN) Target Price Raised to $50 by Morgan Sta - GuruFocus
Dyne Therapeutics (DYN) Stock Sees Significant Drop - GuruFocus
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):